FUJIFILM Cellular Dynamics Opens $200 Million iPSC Manufacturing Facility to Quadruple Production Capacity
核心洞察
FUJIFILM Cellular Dynamics (搜索) opened a new 175,000-square-foot headquarters and iPSC manufacturing facility in Madison, Wisconsin, as part of a $200 million strategic investment by Fujifilm.
The facility is expected to quadruple the company's manufacturing capacity for iPSC-based research products and expand capabilities for next-generation cell therapy development.
The expansion addresses growing demand from pharmaceutical companies for new approach methods (NAMs) in drug discovery as regulatory guidance shifts away from animal testing.
FUJIFILM Cellular Dynamics (搜索) celebrated the opening of its new headquarters and induced pluripotent stem cell (iPSC) development and manufacturing facility in Madison, Wisconsin, marking a significant expansion in the company's capacity to support the growing global market for stem cell-based research and therapeutics. The 175,000-square-foot facility represents part of a $200 million strategic investment by Fujifilm and is expected to quadruple the company's iPSC-based research products and services manufacturing footprint.
Addressing Growing Market Demand
The new facility comes at a critical time as regulatory guidance in the United States and Europe has heightened interest in transitioning away from animal testing toward new approach methods (NAMs). iPSC-derived differentiated cells, which more accurately reproduce human biological functions, have been increasingly adopted in the evaluation of efficacy and safety at the preclinical stage of drug development.
"Completion of this facility comes at a critical time in the iPSC field, where FUJIFILM Cellular Dynamics (搜索) has been setting industry standards for more than 20 years," said Toshihisa Iida, director, corporate vice president, general manager of Life Sciences Strategy Headquarters and Bio CDMO Division, FUJIFILM Corporation, Japan. "This new facility enables us to respond to growing demand from pharmaceutical companies, research institutions, and academia engaged in new drug research and development."
Advanced Manufacturing Capabilities
The facility integrates state-of-the-art capabilities including cell culture manufacturing laboratories, process development laboratories, and a center of excellence for gene editing. These capabilities support both research-grade iPSC products and development services for partners developing next-generation cell therapies. The site will expand manufacturing of the company's iPSC-derived iCell (搜索) product lines, which are increasingly leveraged for NAMs in drug discovery.
The facility is designed to be scalable to accommodate a wide range of processes, from investigational drug manufacturing to commercial production, with an eye toward future demand for contract manufacturing of cell therapy products.
Strategic Impact and Leadership
"The opening of this facility is an exciting milestone for FUJIFILM Cellular Dynamics (搜索) and represents a crucial next step for scaling the infrastructure needed to support the next generation of iPSC-based research and therapeutics in the U.S.," said Tomoyuki Hasegawa, president and CEO of FUJIFILM Cellular Dynamics. "By expanding our development and manufacturing capabilities, we can better support partners working to translate stem cell science into real clinical impact."
The ribbon-cutting celebration was attended by Fujifilm's leadership and state and local public officials, including Wisconsin Gov. Tony Evers, Deputy Secretary Sam Rikkers of Wisconsin Economic Development Corporation, Acting Consul General Naoya Kishi of Japan, and Madison Mayor Satya Rhodes-Conway.
Regional Biotechnology Hub
"FUJIFILM Cellular Dynamics (搜索) is a Wisconsin success story," said Gov. Evers. "Thanks to James Thomson's pioneering stem cell research at the University of Wisconsin-Madison, collaboration between our state's public and private sectors, and global partnerships to carry this innovation forward, we are celebrating not only the growth of one company, but our state's leadership throughout the fields of biohealth and biotechnology."
Delara Motlagh, COO of FUJIFILM Cellular Dynamics (搜索), emphasized the facility's role in reinforcing Madison's position as a global center for stem cell innovation. "The expanded footprint highlights the strength of the region's biotechnology ecosystem while advancing regenerative medicine by supporting customers worldwide," she said.
The expanded capacity will advance development, manufacturing, and commercialization efforts across FUJIFILM Cellular Dynamics (搜索)' portfolio, supporting drug discovery across all therapeutic modalities as the company continues to build its position as a leading developer and manufacturer of human iPSCs (搜索) and iPSC-derived cells.